Newborn affected by maternal use of hallucinogens

This code identifies a newborn whose health status is adversely impacted by the mother's use of hallucinogenic substances during pregnancy. This includes any direct or indirect effects on the neonate resulting from maternal exposure to drugs such as LSD, psilocybin, MDMA, or PCP.

Apply this code when documentation clearly indicates a newborn's condition is attributable to maternal hallucinogen use. This typically involves findings such as withdrawal symptoms, developmental abnormalities, or other adverse health outcomes in the neonate linked to the mother's drug history.

• Ensure documentation explicitly links the newborn's condition to maternal hallucinogen use, not just general drug use.
• Do not use this code for newborns affected by maternal use of other medications; refer to the Excludes2 note for P04.1-.
• Sequence this code as a secondary diagnosis following the primary condition or symptom exhibited by the newborn.